DUBLIN--(BUSINESS WIRE)--The "Skin Burns- Market Insights, Epidemiology and Market Forecast-2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Skin Burns in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Skin Burns from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Study Period: 2017-2028
Epidemiology
According to this research, the incident population of Skin Burns was estimated to be 16,800 [7MM] in 2018. United States accounts for the highest skin-burn cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest incident patient population of Skin Burns, followed France.
Drug Chapters
The treatment regimen of skin burns is mainly classified according to the intensity of the impact and severity of the burn. Moisturizers, over the counter analgesics and /or anti-inflammatory agents, hydration and topical treatments (such as silver releasing agents).
Although silver has been used in the form of salts such as Silver nitrate and silver sulfadiazine (Silvadene; King Pharmaceuticals, Inc.) since the past forty years, the available delivery systems often in the form of a salt have been limiting factors to successful biologic use of this noble metal in burn wound care. Xenografts introduce exogenous collagen into the wound, which aids dermal regeneration.
Some of the commonly used products include Matriderm (Suwelack Skin and Health Care Ag) and Oasis (Healthpoint, Fort Worth). Second degree burns are treated with topical medications in superficial cases. However, for deep burn cases TransCyte (Advanced BioHealing, Inc.) is a dressing that is in use. The primary reason being that they impair fibroblast and epithelial proliferation, which in turn delays healing.
Detailed chapters for all of these drugs along with other marketed therapies have been covered in the report.
Market Outlook
According to this research, the global market of Skin Burns was estimated to be USD 1,452.96 million in 2018. The United States accounts for the largest market size of Skin Burns, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
The most promising candidate which was recently approved by the US FDA is Avita Medical's RECELL System (RECELL Autologous Cell Harvesting Device). It is the first spray-on skin product to win approval for the U.S. market and is expected to transform the way burns are treated worldwide.
The dynamics of Skin Burns market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Key players are working robustly on new therapies with novel mechanism of action, including StrataGraft (Mallinckrodt), CellMist System (RenovaCare).
Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of potential therapies will lead to an increase in the market size of Skin Burns in the coming years.
Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Report Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Report Assessment
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Benefits
- This report will help to develop Business Strategies by understanding the trends shaping and driving the Skin Burns market.
- Organize sales and marketing efforts by identifying the best opportunities for Skin Burns market.
- To understand the future market competition in the Skin Burns market.
Companies Mentioned
- Pfizer
- Avita Medical
- Mallinckrodt
- RenovaCare
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xvrwjn/skin_burns_1_45?w=4
